Russell Glenn Higbee
Veterinary at Discovery Dr, Orlando, FL
License number
Colorado 6680
Issued Date
Dec 22, 1997
Renew Date
Nov 1, 2010
Expiration Date
Oct 31, 2012
Type
Veterinarian
Address
Address
2501 Discovery Dr SUITE 300, Orlando, FL 32826
Professional information
Qa/Qc/Glp/Rso/Bso - Sanofi Pasteur, Vaxdesign Campus
Position:
Manager QA/QC/GLP/RSO/BSO at sanofi pasteur, VaxDesign Campus, Professor, Burnett School of Biomedical Sciences, College of Medicine at University of Central Florida
Location:
Orlando, Florida
Industry:
Biotechnology
Work:
sanofi pasteur, VaxDesign Campus
since 2004
-
Manager QA/QC/GLP/RSO/BSO
University of Central Florida
since 2004
-
Professor, Burnett School of Biomedical Sciences, College of Medicine
Methods Of Evaluating A Test Agent In A Diseased Cell Model
US Patent:
8298824, Oct 30, 2012
Filed:
Sep 20, 2011
Appl. No.:
13/237593
Inventors:
William L. Warren - Orlanda FL, US
Heather Fahlenkamp - Cleveland OK, US
Russell G. Higbee - Orlando FL, US
Eric M. Mishkin - Winter Springs FL, US
Michael D. Rivard - Natick MA, US
Santosh Pawar - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Russell G. Higbee - Orlando FL, US
Eric M. Mishkin - Winter Springs FL, US
Michael D. Rivard - Natick MA, US
Santosh Pawar - Orlando FL, US
Assignee:
Sanofi Pasteur Vaxdesign Corporation - Orlando FL
International Classification:
C12N 5/00, C12N 5/02
US Classification:
435375, 435382, 435404
Abstract:
The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.
Methods Of Evaluating A Test Agent In A Diseased Cell Model
US Patent:
2010027, Nov 4, 2010
Filed:
Jul 9, 2010
Appl. No.:
12/833640
Inventors:
William L. WARREN - Orlando FL, US
Heather FAHLENKAMP - Cleveland OK, US
Russell G. HIGBEE - Orlando FL, US
Eric M. MISHKIN - Winter Springs FL, US
Michael D. RIVARD - Natick MA, US
Santosh PAWAR - Orlando FL, US
Heather FAHLENKAMP - Cleveland OK, US
Russell G. HIGBEE - Orlando FL, US
Eric M. MISHKIN - Winter Springs FL, US
Michael D. RIVARD - Natick MA, US
Santosh PAWAR - Orlando FL, US
Assignee:
VAXDESIGN INC. - Orlando FL
International Classification:
C12Q 1/02, C12Q 1/70
US Classification:
435 5, 435 29
Abstract:
The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the tissues of the immune system in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates and other materials in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interactions with the immune system, coupled with disease models to provide a more complete representation of an immune response.
Methods For Assaying Responses To Vaccines
US Patent:
2011026, Nov 3, 2011
Filed:
Jun 23, 2011
Appl. No.:
13/167131
Inventors:
Selva SUKUMAR - Berkeley CA, US
Mohey Eldin M. EL SHIKH - Richmond VA, US
John G. TEW - Mechanicsville VA, US
Donald DRAKE, III - Orlando FL, US
Luis MOSQUERA - Oviedo FL, US
Eric MISHKIN - Winter Springs FL, US
Anatoly M. KACHURIN - Orlando FL, US
Russell HIGBEE - Orlando FL, US
Conan LI - Los Altos CA, US
William L. WARREN - Orlando FL, US
Heather FAHLENKAMP - Cleveland OK, US
Mohey Eldin M. EL SHIKH - Richmond VA, US
John G. TEW - Mechanicsville VA, US
Donald DRAKE, III - Orlando FL, US
Luis MOSQUERA - Oviedo FL, US
Eric MISHKIN - Winter Springs FL, US
Anatoly M. KACHURIN - Orlando FL, US
Russell HIGBEE - Orlando FL, US
Conan LI - Los Altos CA, US
William L. WARREN - Orlando FL, US
Heather FAHLENKAMP - Cleveland OK, US
Assignee:
SANOFI PASTEUR VAXDESIGN CORPORATION - Orlando FL
International Classification:
C12Q 1/18
US Classification:
435 32
Abstract:
The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.
Immunotherapy Compositions, Method Of Making And Method Of Use Thereof
US Patent:
2010028, Nov 11, 2010
Filed:
Sep 18, 2009
Appl. No.:
12/562432
Inventors:
Russell G. Higbee - Orlando FL, US
Glen N. Barber - Miami FL, US
Glen N. Barber - Miami FL, US
Assignee:
University Of Miami - Miami FL
Vaxdesign Corporation - Orlando FL
Vaxdesign Corporation - Orlando FL
International Classification:
A61K 38/20, A61K 39/00, A61K 39/02, A61K 39/12, A61K 9/14, A61K 9/00, A61K 38/21, A61P 31/12, A61P 31/16, A61P 31/18, A61P 35/00
US Classification:
424486, 4241841, 4242341, 4242741, 4242041, 424490, 424491, 424 852, 424 857, 424 856, 424 855, 4242771
Abstract:
The present invention directs to compositions and methods for modulating immune system. One aspect of the present invention relates to a composition comprising FADD-dependent signaling pathway modulators. Another aspect of the 5 present invention relates to biodegradable microparticles, such as a chitosan microparticic, or PLGA/PEI microparticle, designed to deliver nucleic acids and/or proteins, such as FADD-dependent signaling pathway modulators, to boost different pathways of an immune response. Another aspect of the present invention relates to the method of making biodegradable microparticles. The further aspect of the present invention relates to the use of the chitosan and other polycationic microparticles to deliver FADD-dependent signaling pathway modulators to modulate immune system for the prevention and/or treatment infectious diseases and cancers.
Porous Membrane Device That Promotes The Differentiation Of Monocytes Into Dendritic Cells
US Patent:
2010010, Apr 29, 2010
Filed:
Oct 30, 2009
Appl. No.:
12/609060
Inventors:
Donald DRAKE, III - Orlando FL, US
David MOE - Orlando FL, US
Conan LI - Los Altos CA, US
Heather FAHLENKAMP - Cleveland OK, US
Russell HIGBEE - Orlando FL, US
Robert PARKHILL - Orlando FL, US
William L. WARREN - Orlando FL, US
David MOE - Orlando FL, US
Conan LI - Los Altos CA, US
Heather FAHLENKAMP - Cleveland OK, US
Russell HIGBEE - Orlando FL, US
Robert PARKHILL - Orlando FL, US
William L. WARREN - Orlando FL, US
Assignee:
VaxDesign Corp. - Orlando FL
International Classification:
C12N 5/0784
US Classification:
435372
Abstract:
Dendritic cells (DCs) for research and clinical applications are typically derived from purified blood monocytes that are cultured in a cocktail of cytokines for a week or more. Because it has been suggested that these cytokine-derived DCs may be deficient in some important immunological functions and might not accurately represent antigen-presenting cell (APC) populations found under physiologic conditions, there is a need for methods that allow the generation of DCs in a more physiologically relevant manner. The present invention comprises a simple and reliable technique for generating large numbers of highly purified DCs, based on a single migration of blood monocytes through endothelial cells that are cultured in, for example, a Transwell® device. The resultant APCs, harvested from the lower Transwell® chamber, resemble other in vitro-generated DC populations in their expression of major histocompatibility (MHC) and costimulatory molecules, ability to phagocytose foreign antigens, and capacity to trigger antigen-specific T cell responses.
Artificial Tissue Constructs Comprising Alveolar Cells And Methods For Using The Same
US Patent:
8647837, Feb 11, 2014
Filed:
Jul 16, 2008
Appl. No.:
12/173921
Inventors:
Ayesha Mahmood - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
William Warren - Orlando FL, US
Russell Higbee - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
William Warren - Orlando FL, US
Russell Higbee - Orlando FL, US
Assignee:
Sanofi Pasteur Vaxdesign Corp. - Orlando FL
International Classification:
C12Q 1/68, G01N 33/53, C12Q 1/02
US Classification:
435 41, 435 61, 435 71, 435 29
Abstract:
The present invention comprises artificial tissue constructs that serve as in vitro models of mammalian lung tissue. The artificial tissue constructs of the present invention comprise functionally equivalent in vitro tissue scaffolds that enable immunophysiological function of the lung. The constructs can serve as novel platforms for the study of lung diseases (e. g. , interstitial lung diseases, fibrosis, influenza, RSV) as well as smoke- and smoking-related diseases. The artificial tissue constructs of the present invention comprise the two components of alveolar tissue, epithelial and endothelial cell layers.
Artificial Immune System: Methods For Making And Use
US Patent:
7855074, Dec 21, 2010
Filed:
Apr 28, 2005
Appl. No.:
11/116234
Inventors:
William L. Warren - Orlando FL, US
Heather Fahlenkamp - Oviedo FL, US
Russell Higbee - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
Conan Li - Orlando FL, US
Mike Nguyen - Orlando FL, US
Robert Parkhill - Orlando FL, US
Darrell J. Irvine - Arlington MA, US
Gwendalyn J. Randolph - New York NY, US
Nir Hacohen - Brookline MA, US
Bruce Torbett - Encinitas CA, US
Heather Fahlenkamp - Oviedo FL, US
Russell Higbee - Orlando FL, US
Anatoly Kachurin - Orlando FL, US
Conan Li - Orlando FL, US
Mike Nguyen - Orlando FL, US
Robert Parkhill - Orlando FL, US
Darrell J. Irvine - Arlington MA, US
Gwendalyn J. Randolph - New York NY, US
Nir Hacohen - Brookline MA, US
Bruce Torbett - Encinitas CA, US
Assignee:
VaxDesign Corp. - Orlando FL
International Classification:
C12N 5/08
US Classification:
435372, 435373
Abstract:
The present invention relates to methods of constructing an integrated artificial immune system that comprises appropriate in vitro cellular and tissue constructs or their equivalents to mimic the normal tissues that interact with vaccines in mammals. The artificial immune system can be used to test the efficacy of vaccine candidates in vitro and thus, is useful to accelerate vaccine development and testing drug and chemical interaction with the immune system.
In Vitro Germinal Centers
US Patent:
8003385, Aug 23, 2011
Filed:
Feb 17, 2010
Appl. No.:
12/707563
Inventors:
Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Conan Li - Los Altos CA, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Eric Mishkin - Winter Springs FL, US
William L. Warren - Orlando FL, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Conan Li - Los Altos CA, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Eric Mishkin - Winter Springs FL, US
William L. Warren - Orlando FL, US
Assignee:
Sanofi Pasteur Vax Design Corp. - Orlando FL
International Classification:
C12N 5/06, C12N 5/02
US Classification:
435326, 435375, 435377
Abstract:
The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.
In Vitro Germinal Centers
US Patent:
8003387, Aug 23, 2011
Filed:
Dec 21, 2006
Appl. No.:
11/642938
Inventors:
Selva Sukumar - Berkeley CA, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Eric Mishkin - Winter Springs FL, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Conan Li - Los Altos CA, US
William L. Warren - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Mohey Eldin M. El Shikh - Richmond VA, US
John G. Tew - Mechanicsville VA, US
Donald Drake, III - Orlando FL, US
Luis Mosquera - Oviedo FL, US
Eric Mishkin - Winter Springs FL, US
Anatoly M. Kachurin - Orlando FL, US
Russell Higbee - Orlando FL, US
Conan Li - Los Altos CA, US
William L. Warren - Orlando FL, US
Heather Fahlenkamp - Cleveland OK, US
Assignee:
Sanofi Pasteur Vaxdesign Corp. - Orlando FL
International Classification:
C12N 5/08, C12N 5/00, C12N 5/02
US Classification:
435373, 435375, 435377
Abstract:
The present invention incorporates germinal centers (GCs) into three-dimensional (3D) engineered tissue constructs (ETCs). In an embodiment, we have incorporated the GC in the design of an artificial immune system (AIS) to examine immune responses to vaccines and other compounds. Development of an in vitro GC adds functionality to an AIS, in that it enables generation of an in vitro human humoral response by human B lymphocytes that is accurate and reproducible, without using human subjects. The invention also permits evaluation of, for example, vaccines, allergens, and immunogens, and activation of human B cells specific for a given antigen, which can then be used to generate human antibodies. In an embodiment of the present invention the function of the in vitro GC is enhanced by placing FDCs and other immune cells in a 3D ETC; FDCs appear more effective over a longer time (antibody production is sustained for up to about 14 days.